A new antibody treatment for Alzheimer's disease
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's Disease
['FUNDING_U01'] · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · NIH-10913980
This study is looking at a new treatment that uses a special antibody to block a hormone linked to Alzheimer's disease, and it's testing whether this can help improve thinking and memory in mice, with hopes that it could eventually help people with Alzheimer's.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10913980 on ClinicalTrials.gov |
What this research studies
This research investigates a novel humanized monoclonal antibody, Hu6, designed to block the action of follicle stimulating hormone (FSH), which has been linked to Alzheimer's disease. The study aims to understand how inhibiting FSH can improve cognitive function and potentially prevent Alzheimer's in mouse models. By focusing on the relationship between FSH levels and Alzheimer's pathology, the researchers hope to develop a new therapeutic approach that could benefit patients suffering from this condition. The project includes scaling up the production of the antibody and testing its effectiveness in preclinical models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's disease, particularly postmenopausal women who may have elevated FSH levels.
Not a fit: Patients with advanced Alzheimer's disease or those who do not have elevated FSH levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that improves cognitive function and prevents the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting FSH for various aging disorders, suggesting potential for success in this novel approach for Alzheimer's disease.
Where this research is happening
NEW YORK, UNITED STATES
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZAIDI, MONE — ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- Study coordinator: ZAIDI, MONE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.